Ocugen's primary clinical-stage asset pipelines span advanced Phase 2 and Phase 3 development trials. For instance, its flagship modifier gene therapy candidate, OCU400, completed enrollment for its Phase 3 registration trial targeting retinitis pigmentosa, with rolling Biologics License Application submissions underway. Simultaneously, its OCU410 program targeting geographic atrophy secondary to dry age-related macular degeneration has advanced through positive Phase 2 evaluation milestones, preparing for upcoming Phase 3 registrational trials. Other pipeline assets like OCU200 for diabetic macular edema and OCU500 are progressing through initial phase trials.